SCHEMBL4223367

SCHEMBL4223367

O=C(C=Cc1cnc(NC2CCN(Cc3cccnc3)CC2)c(Cl)c1)NOC1CCCCO1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.42
CXCR4 P61073 1/20 0.41
CHRM2 P08172 1/20 0.41
CHRM1 P11229 1/20 0.41
CHRM3 P20309 1/20 0.41
SIGMAR1 Q99720 2/20 0.41
DRD4 P21917 1/20 0.41
SLC6A5 Q9Y345 1/20 0.40
FLT3 P36888 1/20 0.39
TYRO3 Q06418 1/20 0.39
MERTK Q12866 1/20 0.39
GAS6 Q14393 1/20 0.39
ACHE P22303 1/20 0.39
CACNA1I Q9P0X4 1/20 0.39
HTR4 Q13639 1/20 0.39
MCHR1 Q99705 2/20 0.39
DRD2 P14416 1/20 0.38
HTR2A P28223 1/20 0.38
HTR2C P28335 1/20 0.38
HTR2B P41595 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4223336 1.00 PKM (0.42) PKMCXCR4CHRM2CHRM1CHRM3
SCHEMBL4231673 0.93 HTR2A (0.45) SIGMAR1ACHEDRD2HTR2AHTR2C
SCHEMBL4231670 0.93 HTR2A (0.45) SIGMAR1ACHEDRD2HTR2AHTR2C
SCHEMBL4221311 0.93 MCHR1 (0.40) CHRM2CHRM1CHRM3SIGMAR1MCHR1
SCHEMBL4221290 0.93 MCHR1 (0.40) CHRM2CHRM1CHRM3SIGMAR1MCHR1
SCHEMBL4222042 0.91 ACHE (0.43) SIGMAR1DRD4ACHEMCHR1DRD2
SCHEMBL4222056 0.91 ACHE (0.43) SIGMAR1DRD4ACHEMCHR1DRD2
SCHEMBL4226356 0.90 MCHR1 (0.47) CHRM1ACHEMCHR1HTR2AHDAC1
SCHEMBL4226363 0.90 MCHR1 (0.47) CHRM1ACHEMCHR1HTR2AHDAC1
SCHEMBL4223902 0.89 ACHE (0.42) SIGMAR1ACHEMCHR1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7557127-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2009-07-07 US disclosed
US-20090054464-A1 HDAC INHIBITOR ASTELLAS PHARMA INC. (JP) 2009-02-26 US disclosed
US-7465731-B2 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2008-12-16 US disclosed
US-20060052599-A1 HDAC inhibitor ASTELLAS PHARMA INC. (JP) 2006-03-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060052599-A1 HDAC inhibitor HDAC1, HDAC2, HDAC11 PKM 2683/4885CXCR4 3466/4885CHRM2 3524/4885
US-20090054464-A1 HDAC INHIBITOR HDAC1, HDAC2, HDAC8 PKM 1177/4885CXCR4 3529/4885CHRM2 3636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.